Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics to combine efforts to advance both companies’ drug portfolios. The combined company will focus on moving AstroRx and a diabetes drug being developed by Kadimastem through clinical trials. A Phase…
Mutations in the mitochondrial genome — the set of DNA instructions found inside mitochondria, the powerhouses of cells — may be linked to amyotrophic lateral sclerosis (ALS), a study found. The findings open the door for new ways of diagnosing and treating the disease, researchers said. “We aren’t saying…
This November, I AM ALS, a nonprofit dedicated to helping people — both patients and family members — affected by amyotrophic lateral sclerosis (ALS), is launching a campaign focused on supporting caregivers. The new initiative aims to raise awareness of the unique challenges faced by ALS caregivers. Throughout…
The government of Ontario has committed CA$13 million (around $9.36 million) over three years to provide critical and comprehensive care to people with amyotrophic lateral sclerosis (ALS) who live in the Canadian province. The funding, which was announced in Ontario’s 2024 Fall Economic Statement, will help…
Leal Therapeutics has raised $45 million to continue advancing its pipeline of drugs for diseases of the brain and spinal cord, including a promising new therapy for amyotrophic lateral sclerosis (ALS). The financing round, which follows an earlier $39 million investment, will help Leal move its two lead…
Biotech company Auttx has received a $125,000 grant to advance the development of new molecules that aim to restore normal RNA processing in people with amyotrophic lateral sclerosis (ALS), potentially leading to new treatments for ALS. Messenger RNAs are intermediate molecules that are produced when genes are read to…
Alterations in the activity of ancient viral DNA that have been incorporated into the human genome may contribute to the development of amyotrophic lateral sclerosis (ALS), according to a study led by researchers at King’s College London. While earlier studies had started to identify connections between these ancient viruses…
Avicenna Biosciences has received its first patent covering new ROCK inhibitor compounds that may be used to treat amyotrophic lateral sclerosis (ALS) and similar disorders. The U.S. patent grants Avicenna exclusive rights to pharmaceutical products containing inhibitors of the Rho associated protein kinases 1 and 2 (ROCK1/2). It also…
NurOwn (debamestrocel) is an investigational cell-based therapy designed to slow disease progression and potentially extend survival in people with ALS. It is being developed by BrainStorm Cell Therapeutics to be given as regular intrathecal injections, or into the spinal canal.
Long-term treatment with the cell therapy NurOwn (debamestrocel) was found to significantly extend survival in people with amyotrophic lateral sclerosis (ALS) when compared with a matched control group from previous clinical trials, according to new data. That data, from an expanded access program (EAP), was shared by NurOwn’s…
